GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (FRA:AM6) » Definitions » Sale Of Business

Amicus Therapeutics (FRA:AM6) Sale Of Business : €0.0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics Sale Of Business?

Amicus Therapeutics's sale of business for the three months ended in Mar. 2025 was €0.0 Mil. It means Amicus Therapeutics gained €0.0 Mil from selling business. Amicus Therapeutics's sale of business for the trailing twelve months (TTM) ended in Mar. 2025 was €0.0 Mil.

Compared with last quarter (€0.0 Mil in Dec. 2024 ), Amicus Therapeutics gained the same money from selling business in Mar. 2025 (€0.0 Mil).


Amicus Therapeutics Sale Of Business Historical Data

The historical data trend for Amicus Therapeutics's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Sale Of Business Chart

Amicus Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sale Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Amicus Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Amicus Therapeutics Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amicus Therapeutics Sale Of Business Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Amicus Therapeutics Business Description

Traded in Other Exchanges
Address
47 Hulfish Street, Princeton, NJ, USA, 08542
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics Headlines

No Headlines